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Abstract
Adult onset Still’s disease (AOSD) is a rare inflammatory disorder that remains poorly understood. Its
pathophysiology is yet to be completely elucidated, but is known to consist mainly on a cytokine cascade,
responsible for the systemic manifestations. AOSD diagnosis is usually difficult and delayed, with physicians having
to rule out several other conditions, including cancer or infectious diseases. Prognosis is heterogeneous and difficult
to establish, ranging from benign outcome to chronic destructive polyarthritis and/or life-threatening events. In
addition, treatment remains to be codified, especially considering the development of new drugs. In this
commentary, we attempt to elucidate the complexity of AOSD and to highlight the need of working on prognostic
tools for this disorder. We also discuss the numerous advances that would be useful for patients in the daily
management of this disease.
Please see related article: http://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0738-8.
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Background
More than 100 years after its first clinical description,
adult onset Still’s disease (AOSD) remains challenging to
diagnose and treat, and an understanding of its
pathophysiology is far from being achieved [1]. Even if
the road ahead remains long and difficult, the study con-
ducted by Ruscitti et al. [2] on the prognostic tools of
AOSD represents a new step towards the better manage-
ment of the disease. Their study, one of the largest
published to date, provides confirmation of the impact of
Pouchot’s ‘systemic score’ on AOSD prognosis. Indeed,
these results are of significant importance considering that
patient management is limited by disease complexity at
the diagnosis, prognosis and therapeutic levels.
AOSD is a rare inflammatory disorder, the diagnosis of
which is usually complex and delayed. Indeed, clinical
presentation is heterogeneous and the main clinical fea-
tures (spiking fever, joint involvement, skin rash and
blood neutrophilia), as well as other minor ones
(pharyngitis, lymph node or spleen enlargement, seritis,
myalgia, hepatitis and abdominal pain), are unspecific
[1]. In addition, histological confirmation and relevant
biomarkers are lacking in this entity (notably, determin-
ation of glycosylated ferritin level is deceiving). There-
fore, diagnosis is based on criteria (Yamaguchi’s or
Fautrel’s) developed for classification rather than daily
practice [3, 4]. In fact, AOSD has a diagnosis of
exclusion and physicians have to rule out several other
striking conditions (autoimmune, infectious or malig-
nant diseases) through a complex diagnosis procedure.
Conversely, in some cases, malignancies or infections
have also been reported as triggering factors for AOSD,
making the understanding of clinical presentation even
more complex [1]. Disease complexity also lies in the
pathophysiological mechanisms leading to a cytokine
cascade (typically Th1) through an abnormal response of
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innate immune cells (especially macrophages) following
the activation of Toll-like receptors [1].
Another complexity level is the highly variable prognosis,
which ranges from a limited and benign outcome to chronic
destructive polyarthritis and/or life-threatening involvement
such as visceral complications (heart, kidney, lung or central
nervous system), thrombotic microangiopathy or macro-
phage activation syndrome (MAS; also called reactive hemo-
phagocytic lymphohistiocytosis) [1, 5–8]. Although
exceptional, fatal events have been linked to AOSD-related
complications and infections. Additionally, current treat-
ments (i.e. NSAIDs, glucocorticoids and immunosuppressive
drugs and biotherapies, in some cases) may also be deleteri-
ous, particularly in the long-term. Of note, the classification
[5, 9, 10] distinguishing monocyclic, polycyclic and chronic
AOSD is not useful for patient management, since it does
not integrate severity and a functional and/or vital related
prognosis. More precisely, it remains difficult to predict out-
come at diagnosis and, consequently, drawing management
guidelines presents a major challenge.
Clearly, joint involvement at diagnosis may affect func-
tional prognosis through destructions resembling those
of rheumatoid arthritis [11], while systemic manifesta-
tions can impair vital prognosis [6] (‘dichotomous view’
of AOSD [1]). A fever higher than 39.5 °C mainly occurs
in systemic AOSD, whereas a leukocyte count higher
than 30,000/mm3 and systemic inflammation markers
are correlated with relapses [12]. Increased serum fer-
ritin levels are associated with disease activity and
chronic or recurrent forms of AOSD [7, 12–14]. In
1991, from a study on 62 patients, Pouchot et al. [5] pro-
posed a ‘systemic score’ reaching up to 12 points, and
assigning one point to each of the following manifesta-
tions: fever, skin rash, pleuritis, pneumonia, pericarditis,
liver involvement, spleen involvement, lymphadenop-
athy, leucocytosis > 15,000/mm3, sore throat, myalgia,
and abdominal pain. This score is easy to calculate, but
remains to be validated in further studies.
In their article recently published in BMC Medicine,
Ruscitti et al. [2] report that Pouchot’s ‘systemic score’
[5] successfully predicts a poor outcome in AOSD. More
precisely, a ‘systemic score’ higher than 6 (discriminating
cut-off ≥ 7) and the presence of any complication (MAS,
kidney failure or myocarditis) at diagnosis are associated
with mortality. Ruscitti et al. [2] observed MAS in 13
out of 100 patients recruited in the last 16 years, which
is consistent with values in previous studies (10–15%) [8,
15]. However, death occurred in 10 patients, which is ex-
tremely high and unexepected. In AOSD, MAS is clas-
sically associated with persistent and/or refractory
diseases and has been known to impair vital prognosis,
but not at this level. For example, a recent Korean study
identified 21 MAS among 109 AOSD patients and only
two patients died [15], which is consistent with other
published studies [8, 16]. In another recent study in
Japan, the MAS-related mortality rate was approximately
20% among AOSD patients [17]. Therefore, the high
mortality rate reported by Ruscitti et al. [2] undoubtedly
has an important weight on the results, especially for the
prognostic score, but also simply reflects on the poten-
tial severity of AOSD. Finally, since MAS is in reality a
life-threatening event, this should not modify our per-
ception of these findings.
Conclusions
We hope that physicians will now be interested in Pou-
chot’s score and that further studies will simply confirm it
as a prognostic tool. The discriminating cut-off predictive
of death should also be evaluated and even precised. From
this point of view, the study by Ruscitti et al. [2] represents
an interesting step in the understanding of AOSD clinical
presentation. Interestingly, these findings are in line with
the ‘dichotomous view’ of AOSD [1] and could be helpful
for the therapeutic decision between glucocorticoids alone
or combined with immunosuppressive drugs/biologics as
first-line treatment.
The final issue raised by this study concerns the meth-
odology, whose improvement is crucial for clinical re-
search on AOSD in the near future. In this rare
inflammatory disorder, international or national (as that
by Ruscitti et al. [2]) collaborative studies would provide
the critical mass for pertinent statistical analyses and
validation through evidence-based medicine.
As often observed, prognostic and therapeutic ad-
vances will probably arise from a better understanding
of clinical phenotypes and pathophysiological mecha-
nisms, and from a ‘dismemberment’ of AOSD into sev-
eral entities, analogous to what ensued following the
discovery of biomarkers, such as anti-neutrophil cyto-
plasm antibodies, on the spectrum of ‘polyarteritis
nodosa’ and other vasculitides. The concept of AOSD as
a disorder clinically meeting Yamaguchi’s criteria prob-
ably covers several entities with distinct pathophysio-
logical processes but certain common inflammatory
actors. Will the advances on inflammasome and cyto-
kines help during the following years? Since AOSD is at
the frontier of autoimmune and autoinflammatory disor-
ders, the answer is ‘yes, probably’. In the end, what do
the two forms of AOSD, namely systemic monophasic
AOSD with high inflammation state at onset and
complete recovery after several months versus chronic
AOSD with systemic onset and chronic destructive sero-
negative polyarthritis, have in common? The answer re-
mains: ‘only our perplexity and ignorance…’
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